Morepen Laboratories is currently trading at Rs. 45.05, up by 5.74 points or 14.60% from its previous closing of Rs. 39.31 on the BSE.

The scrip opened at Rs. 44.36 and has touched a high and low of Rs. 45.43 and Rs. 41.60 respectively. So far 2746262 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 70.40 on 12-Jun-2025 and a 52 week low of Rs. 33.47 on 27-Jan-2026.

Last one week high and low of the scrip stood at Rs. 45.43 and Rs. 37.00 respectively. The current market cap of the company is Rs. 2460.31 crore.

The promoters holding in the company stood at 35.65%, while Institutions and Non-Institutions held 2.88% and 61.46% respectively.

Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore from a leading global pharma major.

Supplies under the mandate are expected to commence within the next 4-5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes. This engagement marks one of the most significant single CDMO mandates in the Company’s history, as it scales its global manufacturing footprint.

Built on over four decades of API manufacturing expertise and regulatory credibility, Morepen’s CDMO platform enables deeper collaboration with global pharmaceutical innovators through structured, multi-year supply programs.

The mandate reflects the company’s growing capabilities in regulated markets, supported by internationally accredited facilities including USFDA, WHO-GMP, and EU approvals. With integrated development-to-commercial manufacturing capabilities, Morepen is positioned to support complex scale-ups and long-duration supply frameworks. The company continues to evaluate capacity enhancement and technology investments aligned with its expanding CDMO opportunity pipeline.

Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.